Hi Christina,
Cheryl makes a really good point about the potential issue of "FLC escape".  
FLC escape can occur when a subclonal line of plasma cells begin producing an excess amount of a given free light chain relative to the expected amount of monoclonal heavy chains that it would also normally produce (monoclonal heavy chains are the things measured by your M-spike). 
As I understand it from my readings, one's M-Spike doesn't have to be completely absent in order for there to be a diagnosis of FLC escape. But, as always, I'm not a doc, so please check with one.
Note that FLC escape can "potentially" signal a situation where a subclonal line of plasma cells has developed that may be resistant to the current treatment and/or signal a relapse.  It's not a given that this is what is occurring in your case, but both Cheryl and I are thinking that the rise in your FLC level ought to be discussed further with your doc.
You may want to read through this article:
A Brioli et al, "Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome," Blood, May 2014 (full text)It contains a couple of statements potentially relevant to your case:
In 46 of 54 patients (85%), the increase in involved serum FLC was >200 mg/L, that is the level of increase recommended for defining relapse requiring treatment in the absence of clinical symptoms"
 Also:
Monitoring for light chain escape at relapse provides an excellent tool to study the global impact of intra-clonal heterogeneity. Our observations fit with a model in which different clones have a different secretory behaviour. One clone is able to produce a complete antibody, while the other secretes only FLC. In such a model FLC escape is a marker of a heterogeneous disease and represents the outgrowth of the clone producing only light chains, which is more resistant to therapy. The results presented here provide evidence to support the idea that intra-clonal heterogeneity and clonal evolution is a general feature associated with disease progression and treatment resistance in myeloma. These results also illustrate the importance of disease monitoring using FLC analysis when there is a suspicion of clinical relapse".
Again, we aren't docs by any stretch of the imagination, and we aren't trying to worry you, but it may be wise to get re-tested and to discuss this a bit further with your specialist.
Take care and let us know what happens.